Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INV-2821
- Development stage
- Preclinical
- Lead developer
- Ionova Life Science
- Modality
- Small Molecules
01
Overview
INV-2821 is a small molecule inhibitor of Cyclin-Dependent Kinase 2 (CDK2) currently in preclinical development by Ionova Life Sciences for the treatment of solid tumors. CDK2 plays a critical role in the cell cycle, particularly in the transition from G1 to S phase and during S phase progression, by forming complexes with Cyclin E or Cyclin A. Overexpression or dysregulation of the CDK2/Cyclin E pathway is a known driver in several malignancies, including CCNE1-amplified ovarian and breast cancers. INV-2821 is designed to selectively inhibit CDK2 activity, thereby inducing cell cycle arrest and suppressing tumor cell proliferation.
02
Targets
CDK2 (Cyclin-dependent kinase 2)
Beyond the preview
Go deeper on INV-2821.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INV-2821.